Lexicon Price To Sales Ratio from 2010 to 2024
LXRX Stock | USD 0.81 0.05 5.81% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 281.00406977 | Current Value 208.67 | Quarterly Volatility 727.28731981 |
Check Lexicon Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexicon Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 526.3 K, Interest Expense of 13.8 M or Total Revenue of 1.1 M, as well as many indicators such as Price To Sales Ratio of 209, Dividend Yield of 0.0 or PTB Ratio of 5.52. Lexicon financial statements analysis is a perfect complement when working with Lexicon Pharmaceuticals Valuation or Volatility modules.
Lexicon | Price To Sales Ratio |
Latest Lexicon Pharmaceuticals' Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Lexicon Pharmaceuticals over the last few years. Price to Sales Ratio is figured by comparing Lexicon Pharmaceuticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Lexicon Pharmaceuticals sales, a figure that is much harder to manipulate than other Lexicon Pharmaceuticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Lexicon Pharmaceuticals' Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexicon Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
View | Last Reported 59.69 X | 10 Years Trend |
|
Price To Sales Ratio |
Timeline |
Lexicon Price To Sales Ratio Regression Statistics
Arithmetic Mean | 435.11 | |
Geometric Mean | 78.51 | |
Coefficient Of Variation | 167.15 | |
Mean Deviation | 518.87 | |
Median | 97.86 | |
Standard Deviation | 727.29 | |
Sample Variance | 528,947 | |
Range | 2.3K | |
R-Value | 0.30 | |
Mean Square Error | 519,921 | |
R-Squared | 0.09 | |
Significance | 0.29 | |
Slope | 48.04 | |
Total Sum of Squares | 7.4M |
Lexicon Price To Sales Ratio History
About Lexicon Pharmaceuticals Financial Statements
Lexicon Pharmaceuticals investors use historical fundamental indicators, such as Lexicon Pharmaceuticals' Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Lexicon Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Price To Sales Ratio | 281.00 | 208.67 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexicon Stock Analysis
When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.